T‐VEC, an HSV‐1‐based oncolytic therapy, has demonstrated efficacy in melanoma,[7] partially attributable to the elevated expression of its cognate receptor Nectin‐1 on melanoma cells.[13]. This evidence concerns the gene NECTIN1 and melanoma.